Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA

Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its enc...

Descripción completa

Detalles Bibliográficos
Autores principales: Guagliardo, Roberta, Merckx, Pieterjan, Zamborlin, Agata, De Backer, Lynn, Echaide, Mercedes, Pérez-Gil, Jesus, De Smedt, Stefaan C., Raemdonck, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781292/
https://www.ncbi.nlm.nih.gov/pubmed/31450805
http://dx.doi.org/10.3390/pharmaceutics11090431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781292/
https://www.ncbi.nlm.nih.gov/pubmed/31450805
http://dx.doi.org/10.3390/pharmaceutics11090431

Ejemplares similares